REFRACTORY HODGKIN LYMPHOMA
Clinical trials for REFRACTORY HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for kids with Hard-to-Treat cancers: targeted drug shows promise
Disease control CompletedThis study tested a drug called tazemetostat in 20 children whose cancers had come back or weren't responding to treatment. The children had specific gene changes (EZH2, SMARCB1, or SMARCA4) in their tumors. The goal was to see if the drug could shrink or slow the growth of these…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 26, 2026 08:35 UTC
-
New drug combo may reduce deadly transplant complication in blood cancer patients
Disease control CompletedThis study looked at 174 adults with blood cancers who received a stem cell transplant from an unrelated donor. Researchers compared different combinations of immune-suppressing drugs to find the best way to prevent graft-versus-host disease (GVHD), a serious complication where d…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 26, 2026 08:31 UTC
-
New antibody drug shows promise for tough blood cancers
Disease control CompletedThis early-stage trial tested a drug called flotetuzumab in 13 people with advanced blood cancers that had returned or stopped responding to treatment. The goal was to find the best dose and check for side effects. Flotetuzumab is a lab-made antibody that may stop cancer cells fr…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 22, 2026 14:01 UTC
-
New drug cocktail shows promise for tough lymphomas
Disease control CompletedThis early-phase study tested the safety and best dose of adding olaparib to high-dose chemotherapy for people with lymphomas that returned or didn't respond to treatment. 50 adults aged 18-65 took part. The goal was to see if this combination could work better before a stem cell…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 20, 2026 11:54 UTC
-
Promising combo for Tough-to-Treat hodgkin lymphoma shows progress
Disease control CompletedThis study tested a new combination of a targeted drug (brentuximab vedotin) with standard chemotherapy for people whose Hodgkin lymphoma returned or didn't respond to treatment. The goal was to find the safest dose and see how many patients achieved complete remission. 45 adults…
Matched conditions: REFRACTORY HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Apr 29, 2026 15:03 UTC